Wall Street analysts expect Stryker Corporation (NYSE:SYK) to post $2.99 billion in sales for the current quarter, Zacks reports. Ten analysts have made estimates for Stryker Corporation’s earnings. The lowest sales estimate is $2.98 billion and the highest is $3.00 billion. Stryker Corporation reported sales of $2.83 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 5.7%. The company is expected to issue its next quarterly earnings report on Thursday, October 26th.

According to Zacks, analysts expect that Stryker Corporation will report full-year sales of $2.99 billion for the current financial year, with estimates ranging from $12.23 billion to $12.36 billion. For the next financial year, analysts anticipate that the business will report sales of $13.14 billion per share, with estimates ranging from $12.96 billion to $13.29 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Stryker Corporation.

Stryker Corporation (NYSE:SYK) last announced its earnings results on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The firm had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.98 billion. During the same quarter in the previous year, the company earned $1.39 earnings per share. The firm’s quarterly revenue was up 6.1% compared to the same quarter last year.

Several research firms have recently commented on SYK. BMO Capital Markets reissued a “hold” rating and set a $125.00 price target on shares of Stryker Corporation in a research note on Tuesday, April 11th. Stifel Nicolaus increased their price target on shares of Stryker Corporation from $151.00 to $158.00 and gave the company a “buy” rating in a research note on Friday, July 28th. BidaskClub cut shares of Stryker Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Goldman Sachs Group Inc began coverage on shares of Stryker Corporation in a research note on Tuesday, May 16th. They set a “neutral” rating and a $129.00 price target on the stock. Finally, Cowen and Company set a $150.00 price target on shares of Stryker Corporation and gave the company an “outperform” rating in a research note on Wednesday, April 26th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $144.03.

Shares of Stryker Corporation (SYK) opened at 146.53 on Monday. The company has a market cap of $54.81 billion, a PE ratio of 32.71 and a beta of 0.80. The company’s 50-day moving average price is $142.76 and its 200 day moving average price is $134.44. Stryker Corporation has a one year low of $106.48 and a one year high of $148.84.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be issued a $0.425 dividend. The ex-dividend date is Thursday, September 28th. This represents a $1.70 annualized dividend and a yield of 1.16%. Stryker Corporation’s dividend payout ratio (DPR) is presently 37.95%.

In related news, insider David Floyd sold 19,305 shares of the firm’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total transaction of $2,790,730.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 7.40% of the company’s stock.

Several large investors have recently modified their holdings of the company. Macquarie Group Ltd. raised its stake in shares of Stryker Corporation by 13.3% in the fourth quarter. Macquarie Group Ltd. now owns 103,000 shares of the medical technology company’s stock worth $12,341,000 after buying an additional 12,100 shares during the last quarter. Gulf International Bank UK Ltd raised its stake in shares of Stryker Corporation by 1.3% in the first quarter. Gulf International Bank UK Ltd now owns 104,546 shares of the medical technology company’s stock worth $13,763,000 after buying an additional 1,300 shares during the last quarter. Lynch & Associates IN raised its stake in shares of Stryker Corporation by 0.3% in the first quarter. Lynch & Associates IN now owns 27,450 shares of the medical technology company’s stock worth $3,614,000 after buying an additional 75 shares during the last quarter. Koshinski Asset Management Inc. raised its stake in shares of Stryker Corporation by 428.5% in the first quarter. Koshinski Asset Management Inc. now owns 15,991 shares of the medical technology company’s stock worth $2,105,000 after buying an additional 12,965 shares during the last quarter. Finally, National Pension Service raised its stake in shares of Stryker Corporation by 0.4% in the first quarter. National Pension Service now owns 245,638 shares of the medical technology company’s stock worth $32,412,000 after buying an additional 884 shares during the last quarter. Institutional investors and hedge funds own 74.07% of the company’s stock.

WARNING: “Stryker Corporation (SYK) Expected to Announce Quarterly Sales of $2.99 Billion” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/07/stryker-corporation-syk-expected-to-announce-quarterly-sales-of-2-99-billion.html.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Get a free copy of the Zacks research report on Stryker Corporation (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.